Hydrogen sulphide (H2S) is a gas most commonly associated with the smell of stink bombs, sewage and rotten eggs, but a team of researchers from the Peninsula Medical
More: continued here
The Royal Pharmaceutical Society of Great Britain is this week issuing new guidance for pharmacists on how to assist patients in managing hypertension. The existing guidance has been updated to reflect the changing role of community pharmacists as they take on more clinical responsibility.
More: continued here
May is Hypertension Awareness Month, and a new device in high blood pressure clinical trials is showing promise for treating U.S. hypertension (high blood pressure) patients whose condition is not controlled by drugs. Rheos® Hypertension (HT) Therapy is an implantable device designed to lower high blood pressure - the number one risk factor for stroke, heart and kidney disease.
More: continued here
Even when their blood pressure is kept strictly under control with the best available medicine, African-American patients with chronic kidney disease (CKD) continue to lose their kidney function over time, research led by a Johns Hopkins team shows. The finding suggests that treating CKD in this population may be vastly more complex than researchers had previously thought, with blood pressure control being only one piece of the therapeutic puzzle.
More: continued here
Researchers from Berlin, Germany have identified variations in a gene, which contributes to heart failure in the presence of hypertension. The gene, Ephx2, encodes an enzyme (soluble epoxide hydrolase) that normally degrades specific epoxides. In this case, the epoxides can be cardioprotective in the setting of heart failure but not necessarily relevant for healthy individuals.
More: continued here
GlaxoSmithKline (GSK) announced that the European Commission has issued marketing authorisation for Volibris® (ambrisentan) for the treatment of Pulmonary Arterial Hypertension (PAH) in patients classified as World Health Organisation (WHO) Functional Class II and III, to improve exercise capacity. [i] Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
More: continued here
Boehringer Ingelheim announced that the European Commission has granted marketing authorisation of the new powerful strength of their fixed dose combination antihypertensive drug MicardisPlus® 80/25 in all 27 EU member states. It will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the United Kingdom and the rest of EU, and when approved also in other countries around the world.
More: continued here
Bayer Schering Pharma was granted European marketing authorization for its new antihypertensive fixed dose combination drug PritorPlus® 80/25 and Kinzalkomb® 80/25 (80 mg telmisartan/25 mg hydrochlorothiazide) by the European Commission. The new formulation will be launched in Germany later this month, to be followed soon by selected countries in the EU.
More: continued here
Electronic handheld blood pressure devices are automated blood pressure measuring devices used for measuring blood pressure at regular intervals, without causing inconvenience to the individual’s daily routine. Rising healthcare expenditure and rapidly aging population are key factors contributing towards a rise in demand for such devices, particularly in the developed regions of the world.
More: continued here
Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced that results from the company’s Phase 2a clinical trial evaluating PS433540, its first-in-class Dual Acting Receptor Antagonist (DARA), will be presented as a late-breaking clinical trial at the American Society of Hypertension (ASH) Twenty-Third Annual Scientific Meeting and Exposition in New Orleans, May 14-17, 2008.
More: continued here
